14CONFAP Application of quantitative proteomics to accelerate vaccine development against Schistosomiasis, a neglected tropical disease.

血吸虫病是一种被忽视的热带疾病，由持续居住在血液中的寄生虫引起，是这一应用的重点，并且仍然是巴西的一个重要公共卫生问题。用一种可用的药物治疗并不能防止再次感染，因此有效的疫苗可以加强控制。蠕虫转录组（2003年）和基因组（2009年）的测序促进了后基因组计划。巴西的科学将从英国专家的尖端蛋白质组学技术的注入中大大受益，从而更好地确定寻找新的候选疫苗的方向。如上所述，拟议伙伴之间以前的合作已导致在高影响力期刊上发表文章，这反过来又为巴西和世界各地的疫苗学家的研究提供了信息。蛋白质组学是一个年轻的学科，正在发展成为一项非常复杂的技术，具有巨大的潜力，可以阐明我们在发达国家和发展中国家都面临的许多疾病问题。欧鲁普雷图的集团也处于成长期。拟议中的项目可以作为跳板，与蛋白质组学前沿的英国研究人员领导小组建立更持久的合作。这将对巴西的热带传染病研究产生不可低估的影响。新的合作将注入先进的蛋白质组学技术，以支持和巩固我们期望识别和定量的新蛋白质的库存。我们预计，这一合作将启动新一轮疫苗试验。在这个项目中，我们将应用利物浦开发的技术来分析潜在的候选疫苗。特别是，利物浦将接待来自欧鲁普雷图的科学家和学员，让他们能够使用位于那里的超级设施。此外，来自利物浦的科学家将访问欧鲁普雷托，提供高级培训，并提供一个正式的培训课程，该课程将向其他巴西科学家开放。

Schistosomiasis a neglected tropical disease caused by persistent blood-dwelling parasitic worms, is the focus of this application and remains an important public health problem in Brazil. Treatment with the one available drug does not prevent reinfection so an effective vaccine would enhance control. Sequencing of the worm's transcriptome (2003) and genome (2009) has facilitated post-genomic initiatives. Brazilian science would greatly benefit from an injection of cutting-edge proteomic technologies from UK experts to better orientate the search for novel vaccine candidates. As stated above previous collaborations between the proposed partners have led to publications in high impact journals, which in turn have informed the research of vaccinologists in Brazil and worldwide.Proteomics is a young subject, expanding into a very sophisticated technology with enormous potential to illuminate many of the disease problems we face in the developed and developing world alike. The group in Ouro Preto is also in the growth phase. The proposed project could serve as the springboard to establish a longer-lasting collaboration with a leading group of UK researchers at the cutting edge of Proteomics. The impact that this would have on infectious tropical disease research in Brazil cannot be underestimated. The new collaboration will inject advanced proteomic techniques to underpin and consolidate the inventory of novel proteins we expect to identify and quantitate. We anticipate that the collaboration will kick-start a new round of vaccine testing.In this programme, we will apply technologies developed at Liverpool to the analysis of potential vaccine candidates. In particular, Liverpool will host scientists and trainees from Ouro Preto, giving them access the super facilities that are located there. In addition, scientists from Liverpool will visit Ouro Preto to provide advanced training and to deliver a formal training course that will be open to other Brazilian scientists.